Acurx Pharmaceuticals, Inc. (ACXP) — Stock Valuation & Research

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to…

ACXP key statistics

Price$1.07
Market cap$5.95M
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range1.03-7.54
Beta-2.05

Explore ACXP's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.